Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $6.68 USD
Change Today -0.20 / -2.91%
Volume 20.2K
ARGS On Other Exchanges
Symbol
Exchange
NASDAQ GM
Berlin
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

argos therapeutics inc (ARGS) Snapshot

Open
$6.88
Previous Close
$6.88
Day High
$6.96
Day Low
$6.55
52 Week High
09/10/14 - $10.80
52 Week Low
07/29/14 - $5.61
Market Cap
138.2M
Average Volume 10 Days
26.1K
EPS TTM
$-3.10
Shares Outstanding
20.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ARGOS THERAPEUTICS INC (ARGS)

Related News

No related news articles were found.

argos therapeutics inc (ARGS) Related Businessweek News

No Related Businessweek News Found

argos therapeutics inc (ARGS) Details

Argos Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of personalized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on Arcelis, its proprietary technology platform. Its development stage products include AGS-003, which is under Phase III clinical trials for the treatment of metastatic renal cell carcinoma and other cancers; and AGS-004, which is in phase 2 clinical trial for the treatment of Human Immunodeficiency Virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is headquartered in Durham, North Carolina.

113 Employees
Last Reported Date: 03/31/15
Founded in 1997

argos therapeutics inc (ARGS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $543.6K
Chief Operating officer and Vice President of...
Total Annual Compensation: $357.0K
Chief Scientific Officer and Vice President o...
Total Annual Compensation: $382.5K
Compensation as of Fiscal Year 2014.

argos therapeutics inc (ARGS) Key Developments

Argos Therapeutics Hires John D. Menditto as Vice President of Corporate Communications and Investor Relations

Argos Therapeutics Inc. announced that John D. Menditto has joined the Company as vice president of corporate communications and investor relations. Mr. Menditto will report directly to Jeff Abbey, president and CEO of Argos. Mr. Menditto comes to Argos with over 20 years of experience in the investor and corporate communications field. He has served as director, investor relations at Novartis Corporation and senior director at Medco Health Solutions. He has also spent a number of years as a communications consultant, including, more recently, as head of investor relations, The Americas, at the Imagination Group.

Argos Therapeutics, Inc. - Special Call

To discuss With Principal Investigator Dr. Robert Figlin the ADAPT trial update presented at ASCO and the IDMC recommendation to continue the trial

Argos Therapeutics, Inc., Annual General Meeting, Jun 17, 2015

Argos Therapeutics, Inc., Annual General Meeting, Jun 17, 2015., at 10:00 Eastern Daylight. Location: Wilmer Cutler Pickering Hale and Dorr LLP. Agenda: The election of three class I directors, each to serve for a three-year term expiring at the 2018 annual meeting of stockholders; to consider ratification of the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2015; and to consider the transaction of any other business that may properly come before the annual meeting or any adjournment thereof.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARGS:US $6.68 USD -0.20

ARGS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advaxis Inc $18.48 USD -0.44
Dynavax Technologies Corp $23.57 USD +0.33
Eurocine Vaccines AB kr2.00 SEK -0.04
Genocea Biosciences Inc $13.52 USD -0.40
GenVec Inc $2.04 USD -0.05
View Industry Companies
 

Industry Analysis

ARGS

Industry Average

Valuation ARGS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 99.5x
Price/Book 9.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 56.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARGOS THERAPEUTICS INC, please visit www.argostherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.